Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › RVMD

Revolution Medicines

RVMD Lead: Approved 5 Biotech Distilled articles ↓ 30 filings & releases ↓ Cash $616M (Sep 30, 2026) ↓ 5 verdicts ↓ 9 timing quotes ↓
Oncology Small Molecule

Market cap $41.6B 216.3M shares (10-Q, Oct 30, 2026) × $192.28 close Nov 6, 2026

Most recent annual filing: 2026-02-25

Catalyst timeline

9 trackedQuarter catalyst calendar →
  1. RASolve 301 daraxonrasib enrollment done2026RASolve 301 daraxonrasib enrollment done, 2026, routine
  2. RMC-5127 readout2H 2026RMC-5127 readout, 2H 2026, notable
  3. RASolve 307 / elironrasib trial4Q 2026RASolve 307 / elironrasib trial, 4Q 2026, notable
  4. RM-055 trial start4Q 2026RM-055 trial start, 4Q 2026, notable
  5. RASONQUE daraxonrasib corporate updateNov 2026RASONQUE daraxonrasib corporate update, Nov 2026, material
  6. RVMD commercial print launchNov 2026RVMD commercial print launch, Nov 2026, notable
  7. RASolve 301 daraxonrasib topline2027RASolve 301 daraxonrasib topline, 2027, major
  8. RMC-5127 RASolve readout2027RMC-5127 RASolve readout, 2027, notable
  9. RASolute 303 enrollment done1H 2027RASolute 303 enrollment done, 1H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (11 active programs)

Technology platforms

tri-complex technology platform

Proprietary tri-complex platform enabling inhibition of the active GTP-bound form of RAS (RAS(ON)); used to design small molecule RAS(ON) inhibitors targeting multiple oncogenic RAS variants across cancer indications including PDAC, NSCLC, and CRC

Targets: RAS

Capital (as filed)

Cash
$616M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$3.04B Sep 30, 2026
Operating cash flow
−$416M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$3.65B cash per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Revolution Medicines, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-08-27 Watch Revolution Medicines (RVMD) — Scientific Deep Dive for RASONQUE (daraxonrasib) and the RAS(ON) Pipeline The binary is spent and the valuation at ~12× realized peak sales still embeds expansion credit; wait for the first two commercial prints to confirm launch execution before entering.
  2. 2026-09-15 Watch UPDATE: Revolution Medicines (RVMD) - The FDA Just Tipped Its Hand on Front-Line BTD for the 1L combination improves the regulatory path but supplies no new efficacy data; the upgrade trigger remains the first two commercial prints in November 2026 and February 2027.
  3. 2026-10-14 Watch UPDATE: Revolution Medicines (RVMD) - The Money They Turned Down Management declining the optional Royalty Pharma Tranche 3 royalty sale is a constructive signal on expected sales, but the November revenue print remains the only thing that can move the thesis.
  4. 2026-10-16 Watch UPDATE: Revolution Medicines (RVMD) - Europe Says Yes, and the Survival Curve Grows Up EU approval path and a matured survival signal (HR 0.49) that held up both de-risk the asset, but launch-execution and net-price questions remain the whole argument at ~12× realized peak.
  5. 2026-11-05 Buy core UPDATE: Revolution Medicines (RVMD) - The Register Rang The first commercial quarter cleared the launch-execution hurdle on every disclosed metric (5,000+ patients, >90% payer coverage, NCCN Category 1 Preferred) and RASolute 303 is finally date-stamped, justifying starting a partial position staged into the February confirmation print.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (9 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (30)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 26, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)